New class of targeted radioactive treatment effective for men with metastatic prostate cancer
TheraP is the first randomised trial comparing a novel radioactive treatment called 177Lu-PSMA-617 (Lu-PSMA), to the current standard-of-care chemotherapy called cabazitaxel for men with advanced prostate cancer. The men who have taken part in this trial had prostate cancer that had already progressed after standard chemotherapy. This exciting trial is a partnership between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) with support from the Australian Nuclear Science and Technology Organisation (ANSTO), Endocyte, It’s a Bloke Thing, Movember and CAN4CANCER. This trial has now reached a point where interim results have been reported at the American Society of Clinical Oncology Virtual Meeting 2020 – the largest annual oncology scientific meeting – at the end of May 2020.
“This clinical trial provides compelling evidence that Lu-PSMA represents a new class of effective therapy for men with advanced prostate cancer. The ability to see what you treat by using the same molecule for both scanning and treatment is remarkable. This enables personalised and patientcentred care where patients most likely to benefit can be carefully selected...” Study Chair Professor Michael Hofman
A LITTLE BELOW THE BELT 23